MBP and myeloid sarcoma: The findings showing that DQB1*06:02 determines pathogenic autoimmunity against PLP (11) and MOBP (10) together with previously reported studies showing that DRB1*15:01 determines pathogenic autoimmunity against MBP and MOG (8, 9) suggest a more complex and differential genetic predisposition to HLA-DR15+ MS, depending on the primary CNS target antigen/epitope against which the pathogenic autoimmunity is primarily directed (or triggered).